A comprehensive narrative review published in Neurology and Therapy evaluates strategies for optimizing long-term anti-CD20 monoclonal antibody therapies in multiple sclerosis and other autoimmune disorders affecting the central nervous system. Conducted jointly by the Steering Committees of the Italian Neuroimmunology Association and the Neuroimmunology Study Group of the Italian Society of Neurology, the analysis examines whether reducing cumulative exposure through extended interval dosing, dose reduction, or B-cell-guided retreatment can mitigate emerging infectious complications while maintaining clinical and radiological disease suppression. Anti-CD20 antibodies such as ocrelizumab, ofatumumab, and ublituximab are officially approved for multiple sclerosis, whereas rituximab is frequently prescribed off-label across multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and autoimmune encephalitis. While these agents robustly suppress relapses and neuroinflammatory lesion activity by inducing prolonged peripheral B-cell depletion, accumulating evidence indicates that prolonged exposure significantly increases the risk of severe infections, progressive hypogammaglobulinemia, and impaired vaccine-induced humoral immunity.
The biological rationale for targeting CD20 lies in the specific developmental timeline of the B-cell lineage. The CD20 surface antigen is expressed starting from late pre-B-cell stages and persists through mature and memory B-cell populations, but it is entirely absent on terminally differentiated plasma cells. Consequently, anti-CD20 monoclonal antibodies selectively deplete circulating mature and memory B cells while leaving long-lived plasma cells intact. This selective elimination disrupts critical antigen presentation mechanisms, co-stimulatory signaling, and pro-inflammatory cytokine secretion rather than causing an immediate collapse of all pre-existing antibody production. In multiple sclerosis, memory B cells play a central pathogenic role by activating brain-homing autoreactive CD4+ T cells in an HLA-DR-dependent manner, and their repopulation correlates much more closely with disease reactivation than overall CD19+ B-cell counts. Furthermore, a minor subpopulation representing roughly 2% to 6% of circulating T cells, predominantly within effector and memory CD4+ and CD8+ subsets, also expresses CD20 acquired via trogocytosis. These CD20+ T cells exhibit a distinct pro-inflammatory phenotype with elevated production of interferon-gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha, and are co-depleted alongside B cells during anti-CD20 administration.
Despite the pronounced clinical efficacy demonstrated in pivotal clinical trials, sustained anti-CD20 therapy poses significant long-term safety challenges. Prolonged administration impairs the replenishment of the peripheral B-cell and plasmablast compartments, which can compound age-related declines in bone marrow lymphopoiesis and lead to secondary hypogammaglobulinemia. Observational studies demonstrate that immunoglobulin G and immunoglobulin M levels drop progressively over time, with hypogammaglobulinemia developing in approximately 11% to 20% of treated patients and immunoglobulin G reduction correlating with an increased risk of severe infections carrying an odds ratio of approximately 2.6. In addition to quantitative immunoglobulin declines, treatment-associated infection risks are amplified by clinical vulnerability factors, including older age, progressive multiple sclerosis phenotypes, higher baseline disability scores, obesity, and co-occurring medical conditions. Pivotal trials established that while overall infection rates were broadly comparable to control groups, long-term exposure elevated the prevalence of severe respiratory tract infections, urinary tract complications, and severe COVID-19. Anti-CD20 therapies also markedly diminish vaccine-induced antibody responses, although cellular immunity mediated by T cells is partially preserved.
To counteract the progressive hazards of cumulative immunosuppression, investigators have increasingly evaluated extended interval dosing, moving beyond the standard six-month infusion schedule. Initial insights emerged during the COVID-19 pandemic when clinical service disruptions and safety concerns forced treatment delays. Observational studies revealed that extending the interval between ocrelizumab infusions from the conventional six months to seven, nine, or even twelve months did not lead to a widespread loss of disease control in clinically stable patients. Across several retrospective cohorts, patients managed under extended intervals maintained comparable short-term outcomes regarding relapse rates, disability worsening, and the preservation of no evidence of activity-3 (NEDA-3) status. Immunological investigations revealed that while extended intervals permit partial peripheral CD19+ B-cell reconstitution, the repopulating cells predominantly exhibit a naïve or regulatory phenotype rather than an enrichment of pathogenic memory B cells, providing a biological foundation for durable disease suppression.
Support for extended interval schedules is further reinforced by target trial emulations and preliminary clinical trial findings. In a large target trial emulation focusing on rituximab-treated relapsing multiple sclerosis, transitioning patients who had achieved NEDA-3 status for one year to an extended twelve-month low-dose schedule did not increase the risk of relapses, magnetic resonance imaging lesion activity, or NEDA-3 failure over up to four years of follow-up. Complementing these observations, preliminary randomized data from the Swedish multicenter RIDOSE study presented at ECTRIMS 2025 evaluated 200 patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome. Patients randomized to receive 500 mg of rituximab every twelve months demonstrated outcomes comparable to those receiving 500 mg every six months across years two to four, with a hazard ratio of 0.93 for losing NEDA-3 status and similar overall failure rates of 13.59% versus 12.62%, despite noticeably higher peripheral CD19+ B-cell counts in the extended interval cohort.
In addition to maintaining disease suppression, extending treatment intervals shows favorable immunological and safety trends. Real-world studies indicate that extended interval dosing significantly attenuates the longitudinal decline of serum immunoglobulin G concentrations compared to standard six-month schedules. Patients managed under extended or B-cell-adapted regimens exhibit higher rates of seroconversion and generate more robust antibody titers following vaccination, reflecting a more physiological and gradual pattern of immune reconstitution. Several observational cohorts have reported lower rates of serious infections requiring hospitalization or antimicrobial therapy without sacrificing inflammatory disease control. However, the authors emphasize that current evidence remains largely retrospective, characterized by small sample sizes, short follow-up periods, and potential selection bias, as extended dosing is disproportionately offered to patients who are already clinically stable or who demonstrate early laboratory signs of hypogammaglobulinemia. Ongoing prospective clinical trials, including the BLOOMS and WINDOCRE studies, are currently evaluating B-cell-tailored and annual dosing regimens to provide definitive controlled evidence.
The review outlines practical clinical considerations for implementing personalized de-escalation strategies in multiple sclerosis, defining candidate stability operationally as the absence of clinical relapses, new or enlarging magnetic resonance imaging lesions, and confirmed disability progression for at least 12 to 24 months. For eligible individuals, modest interval extension to approximately seven to nine months represents the most evidence-supported de-escalation step, particularly when recurrent infections occur alongside risk factors such as declining immunoglobulins, older age, or elevated disability. Longer extensions, such as annual rituximab administration, warrant close clinical and imaging surveillance. Biomarker-guided retreatment using total CD19+ or CD19+CD27+ memory B-cell counts provides an individualized alternative, though specific thresholds such as CD19+ cells reaching 10 per microliter or memory B cells reaching 1 per microliter remain unvalidated pragmatic markers. Conversely, de-escalation should be avoided in patients with recent inflammatory activity, highly active baseline disease, or confirmed disability worsening.
Beyond multiple sclerosis, the clinical context and safety considerations for anti-CD20 therapies diverge substantially across other neuroinflammatory conditions. In neuromyelitis optica spectrum disorder, where pathogenic antibodies target astrocytic aquaporin-4 water channels, rituximab has served as an effective primary therapy for nearly two decades. However, complete treatment withdrawal in aquaporin-4-positive patients carries an exceptionally high risk of severe and disabling relapses, making lifelong immunosuppression necessary. Because the prevalence of hypogammaglobulinemia rises from 1.2% after one year to approximately 41% after fourteen years of continuous rituximab exposure, dose-reduction strategies and biomarker-guided reinfusions using CD19+ or memory B-cell thresholds have been adopted. In contrast, in myelin oligodendrocyte glycoprotein antibody-associated disease, rituximab demonstrates lower efficacy, with 37% to 61% of treated patients experiencing relapses that often occur despite profound peripheral B-cell depletion, reflecting a distinct pathophysiology where B-cell depletion alone provides incomplete protection.
In autoimmune encephalitis, anti-CD20 efficacy is heavily dictated by the molecular localization of the target antigen. Rituximab demonstrates robust clinical benefit in subtypes driven by antibodies against neuronal cell surface or synaptic antigens, including NMDAR, LGI1, and CASPR2, where pathogenic antibodies directly bind their targets in vivo. Early administration of rituximab in anti-NMDAR encephalitis reduces relapse risk by approximately 60% and promotes favorable functional recovery, while in anti-LGI1 encephalitis it achieves a tenfold reduction in relapse risk. In contrast, encephalitis associated with intracellular or onconeural antigens, such as anti-GAD65 or paraneoplastic syndromes, involves T-cell-mediated cytotoxic mechanisms and responds poorly to selective B-cell depletion. While single induction courses frequently suffice for anti-NMDAR encephalitis, recurring or refractory surface-antibody cases may warrant maintenance courses tailored to individual clinical recovery and B-cell repopulation.
Ultimately, the Italian collaborative review concludes that while anti-CD20 therapies remain indispensable across central nervous system autoimmune disorders, the therapeutic paradigm must evolve from rigid, lifelong standard dosing toward individualized risk-mitigating strategies. Reducing cumulative drug exposure through extended interval dosing or biomarker-guided retreatment represents a highly promising avenue to curb long-term infectious morbidity and preserve humoral immune function in stable multiple sclerosis. Nevertheless, the authors caution that because the existing literature consists primarily of retrospective observational studies and real-world registries, these strategies do not yet constitute formal standardized practice guidelines. Rigorous prospective randomized trials will be essential to establish validated dosing intervals, verify optimal biomarker thresholds, and confirm whether exposure reduction can safely deliver durable, lifelong neuroprotection.
Subject of Research: Anti-CD20 monoclonal antibody treatment optimization and extended interval dosing in central nervous system autoimmune disorders
Article Title: Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review
Article References: Ferraro, D., Abbadessa, G., Azzolini, F., Bianco, A., Carta, S., Dinoto, A., Di Sante, G., Maniscalco, G. T., Mariotto, S., Constantin, G., Di Filippo, M., Iorio, R., Magliozzi, R., Mechelli, R., Procaccini, C., Signoriello, E., & Centonze, D. (2026). Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review. Neurology and Therapy. https://doi.org/10.1007/s40120-026-01048-1
Image Credits: AI Generated
DOI: 10.1007/s40120-026-01048-1
Keywords: anti-CD20 therapies, multiple sclerosis, extended interval dosing, ocrelizumab, rituximab, hypogammaglobulinemia, B-cell depletion, neuromyelitis optica spectrum disorder, MOGAD, autoimmune encephalitis, infection risk, memory B cells, neuroimmunology, disease-modifying therapy, treatment de-escalation, NEDA-3, vaccine responsiveness
News Source: Kristina Jarvis. (November 20, 2026). Extended Anti-CD20 Dosing Shows Promise for Multiple Sclerosis Safety. Scienmag.



